Circulate Health Secures $12 Million for Longevity Innovations
In a significant step forward in the field of longevity, Circulate Health has successfully raised $12 million in seed funding. This financing is primarily led by Khosla Ventures and marks a pivotal moment for the company as it continues its mission to harness the potential of therapeutic plasma exchange (TPE) to enhance human healthspan and lifespan.
The recent funding announcement follows the release of Circulate's groundbreaking trial study, which is the first to demonstrate how TPE can effectively improve healthspan and reduce biological age. This innovative approach focuses on utilizing TPE to manage inflammation and address chronic diseases.
Innovative Approach to Therapeutic Plasma Exchange
Circulate Health specializes in a unique method of therapeutic plasma exchange that separates, removes, and replaces a patient's plasma. This technology is designed to treat chronic conditions and improve overall health. For the past three years, Circulate has operated quietly, focusing on research that aids in enhancing the human healthspan and tackling the hallmarks of aging through its clinics.
Expansion Plans and Clinic Partnerships
Having established partnerships with various clinics nationwide, Circulate plans to broaden its reach, seeking to expand globally. CEO and co-founder Brad Younggren emphasized the importance of this funding: "We are deeply dedicated to our research and providing high-quality medical care. Our goal is to improve access to therapies that can enhance healthspan and biological markers of aging."
Clinical Trials and Research Findings
A recent clinical trial led by Circulate in collaboration with renowned scientists has yielded promising results. This research showed that TPE combined with intravenous immunoglobulin (IVIG) could reduce patients' biological age by an average of 2.6 years, assessed through various biomarkers.
According to Younggren, Khosla Ventures' investment is a strong validation of Circulate's commitment and potential. The additional capital will be instrumental in expanding their clinic network, enhancing accessibility, and promoting innovative therapies that improve health outcomes.
Expert Guidance and Advisory Board
Circulate Health is backed by a robust scientific advisory board, including experts like Matt Kaeberlein PhD and Alex Aravanis MD PhD, who provide strategic insights to further enhance its offerings. Their expertise contributes significantly to Circulate's mission of pushing the boundaries of health intervention.
Future of Therapeutic Plasma Exchange
Currently, Circulate Health operates 24 partner clinics across eight states, with a target to expand to over 50 clinics by the end of the year. This growth will not only facilitate more extensive coverage but also allow a broader audience to participate in therapies backed by scientific research.
As Circulate Health continues to advance its programs and partnerships, it remains committed to providing insights and educational resources for clinicians and patients keen on exploring the benefits of TPE.
Frequently Asked Questions
What is Circulate Health's primary focus?
Circulate Health focuses on improving healthspan and reducing biological age through therapeutic plasma exchange (TPE).
How much funding did Circulate Health raise?
Circulate Health raised $12 million in seed funding to support its research and clinic expansion.
What are the benefits of therapeutic plasma exchange?
TPE is used to treat inflammation and certain chronic diseases, aiming to enhance overall health and potentially reduce biological age.
Who is leading the funding round for Circulate Health?
Khosla Ventures is leading the current financing round for Circulate Health.
Where can I find more information about Circulate Health?
More information on Circulate Health can be found at their official website.
